SFG
XLO icon

SevenBridge Financial Group’s Xilio Therapeutics XLO Stock Holding History

SevenBridge Financial Group’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,786
Closed -$19.3K – 217
2025
Q3 		$19.3K Hold
1,786
– – ﹤0.01% 212
2025
Q2 		$17.5K Sell
1,786
-1,500
-46% -$15.8K ﹤0.01% 218
2025
Q1 		$33.6K Buy
3,286
+357
+12% +$4.49K 0.01% 219
2024
Q4 		$26.9K Hold
2,929
– – 0.01% 222
2024
Q3 		$44.7K Hold
2,929
– – 0.01% 222
2024
Q2 		$37.2K Buy
2,929
+715
+32% +$11.2K 0.01% 206
2024
Q1 		$36.6K Buy
+2,214
New +$21.4K 0.01% 199

Other funds holding XLO

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

SevenBridge Financial Group's XLO Position: Q4 2025 in Review

SevenBridge Financial Group sold out of Xilio Therapeutics (XLO) in Q4 2025, closing a stake of 1,786 shares — an estimated $19.3K sold.

SevenBridge Financial Group first reported a position in XLO in Q1 2024 and held it in 7 quarters. The position peaked at $44.7K in Q3 2024. 37 funds tracked by Wall St. Rank hold XLO as of Q4 2025.

  • SevenBridge Financial Group reported no remaining Xilio Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SevenBridge Financial Group sold 1,786 Xilio Therapeutics shares in Q4 2025, an estimated $19.3K.
  • SevenBridge Financial Group first reported a position in Xilio Therapeutics in Q1 2024 and held it in 7 quarters.
  • SevenBridge Financial Group's Xilio Therapeutics position peaked at $44.7K in Q3 2024.
  • 37 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2025.

Based on SevenBridge Financial Group's 13F filing for Q4 2025, filed 2 Feb 2026.